Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vivoryon Therapeutics N.V. has announced promising new data showing that its drug varoglutamstat significantly improves kidney function in diabetic patients. In addition to kidney benefits, the treatment also exhibited potential health improvements including weight loss and lower blood pressure without notable adverse events. The company is now planning to advance the drug into a Phase 2 clinical study for diabetic kidney disease.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.